117 results
8-K
EX-1.1
WINT
Windtree Therapeutics Inc
17 Jun 10
Discovery Labs Prices $10.0 Million Public Offering of
12:00am
Prospectus (as defined below) and the information included on Schedule A hereto, all considered together (collectively, the “General Disclosure Package … considered together with the General Disclosure Package, included or will include, any untrue statement of a material fact or omitted
8-K
EX-1.1
WINT
Windtree Therapeutics Inc
16 Mar 12
Discovery Labs Prices $45.0 Million Public Offering of
12:00am
considered together (collectively, the “General Disclosure Package”), (ii) any individual Limited Use Free Writing Prospectus (as defined below) issued … , that has been made available without restriction to any person, when considered together with the General Disclosure Package, included or will include, any
8-K
EX-1.1
WINT
Windtree Therapeutics Inc
16 Feb 11
Discovery Labs Prices $23.5 Million Public Offering of
12:00am
considered together (collectively, the “General Disclosure Package”), (ii) any individual Limited Use Free Writing Prospectus (as defined below) issued … , that has been made available without restriction to any person, when considered together with the General Disclosure Package, included or will include
8-K
EX-1.1
WINT
Windtree Therapeutics Inc
18 Feb 10
Discovery Labs Prices $16.5 Million Public Offering of
12:00am
) and the information included on Schedule A hereto, all considered together (collectively, the “General Disclosure Package”), (ii) any individual Limited Use … with the General Disclosure Package, included or will include, any untrue statement of a material fact or omitted or as of the Closing Date will omit, to state
8-K
EX-10.1
WINT
Windtree Therapeutics Inc
8 May 09
Discovery Labs to Raise $11.3 Million in Registered Direct Offering
12:00am
on Schedule A hereto, all considered together (collectively, the “General Disclosure Package”), (ii) any individual Limited Use Free Writing Prospectus … and Regulations), if any, that has been made available without restriction to any person, when considered together with the General Disclosure Package
8-K
EX-1.1
4juoze8v u9
31 Oct 13
Discovery Labs Prices $50 Million Public Offering of
12:00am
8-K
EX-99.1
edvf6pt
29 May 08
Other Events
12:00am
8-K
EX-99.1
o3hb64qxtqma
28 Sep 06
Discovery Labs Updates Progress on Manufacturing Remediation and Surfaxin® FDA Regulatory Matters
12:00am
8-K
EX-10.1
bs3au1r9rg
13 Feb 13
Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
12:00am
8-K
bapzga4ll0ldmwsoo
18 Apr 06
Other Events
12:00am
8-K
EX-99.2
ftsanl8e8k4x
8 May 08
Discovery Labs Reports First Quarter 2008 Financial Results
12:00am
8-K
EX-99.1
dni0dde87s6x9
24 Jun 08
Discovery Labs and FDA Meet to Clarify Limited Items in SURFAXIN Approvable Letter
12:00am
8-K
EX-10.1
echprlbfiw d2n
13 Oct 10
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.3
0gtha4ufz6kgum pfa1
28 Apr 10
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
8ng8r6
22 Jan 07
Discovery Labs and FDA Reach Clarity on Path Towards Surfaxin® RDS Approval
12:00am
8-K
cmou9dhx
9 Feb 11
Other Events
12:00am
8-K
EX-10.2
e7o87nr5
8 May 09
Discovery Labs to Raise $11.3 Million in Registered Direct Offering
12:00am
8-K
vvceo1pmm7 kz2d6a
12 Oct 06
Other Events
12:00am
8-K
6m3k9iq8p6snqgldfyqt
29 May 08
Other Events
12:00am